OP Asset Management Ltd Invests $2.41 Million in MiMedx Group, Inc $MDXG

OP Asset Management Ltd purchased a new stake in MiMedx Group, Inc (NASDAQ:MDXG) in the first quarter, according to its most recent filing with the SEC. The fund purchased 609,112 shares of the company’s stock, valued at approximately $2,406,000. OP Asset Management Ltd owned about 0.41% of MiMedx Group at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Royal Bank of Canada boosted its holdings in MiMedx Group by 1.4% in the first quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock worth $7,466,000 after purchasing an additional 13,629 shares during the period. AQR Capital Management LLC raised its holdings in shares of MiMedx Group by 42.6% during the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after purchasing an additional 4,296 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of MiMedx Group during the first quarter worth $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of MiMedx Group by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after buying an additional 4,049 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of MiMedx Group by 93.9% in the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock valued at $9,355,000 after buying an additional 596,016 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MDXG has been the subject of a number of recent research reports. Craig Hallum lowered their price objective on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Weiss Ratings cut shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Wall Street Zen downgraded MiMedx Group from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Citizens Jmp lowered their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a report on Thursday, April 30th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

MiMedx Group Trading Up 3.1%

NASDAQ:MDXG opened at $3.93 on Friday. The stock has a market cap of $585.37 million, a price-to-earnings ratio of 19.65 and a beta of 1.48. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39. MiMedx Group, Inc has a 1 year low of $3.03 and a 1 year high of $7.99. The business has a fifty day moving average of $3.59 and a 200-day moving average of $4.71.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. The business had revenue of $58.99 million during the quarter, compared to the consensus estimate of $65.80 million. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. Equities analysts predict that MiMedx Group, Inc will post -0.01 earnings per share for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.